Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;472(5):807-814.
doi: 10.1007/s00428-018-2305-5. Epub 2018 Feb 1.

The landscape of genetic alterations in ameloblastomas relates to clinical features

Affiliations

The landscape of genetic alterations in ameloblastomas relates to clinical features

Sibel Elif Gültekin et al. Virchows Arch. 2018 May.

Abstract

Ameloblastoma is a mostly benign, but locally invasive odontogenic tumor eliciting frequent relapses and significant morbidity. Recently, mutually exclusive mutations in BRAF and SMO were identified causing constitutive activation of MAPK and hedgehog signaling pathways. To explore further such clinically relevant genotype-phenotype correlations, we here comprehensively analyzed a large series of ameloblastomas (98 paraffin block of 76 patients) with respect to genomic alterations, clinical presentation, and histological features collected from the archives of three different pathology centers in France, Germany, and Turkey. In good agreement with previously published data, we observed BRAF mutations almost exclusively in mandibular tumors, SMO mutations predominantly in maxillary tumors, and single mutations in EGFR, KRAS, and NRAS. KRAS, NRAS, PIK3CA, PTEN, CDKN2A, FGFR, and CTNNB1 mutations co-occurred in the background of either BRAF or SMO mutations. Strikingly, multiple mutations were exclusively observed in European patients, in solid ameloblastomas and were associated with a very high risk for recurrence. In contrast, tumors with a single BRAF mutation revealed a lower risk for relapse. We here establish a comprehensive landscape of mutations in the MAPK and hedgehog signaling pathways relating to clinical features of ameloblastoma. Our data suggest that ameloblastomas harboring single BRAF mutations are excellent candidates for neo-adjuvant therapies with combined BRAF/MEK inhibitors and that the risk of recurrence maybe stratified based on the mutational spectrum.

Keywords: Ameloblastoma; Genotype-phenotype correlation; Hedgehog signaling; MAPKinase signaling; Mutation-based risk stratification; Mutational risk profiling.

PubMed Disclaimer

Conflict of interest statement

Ethical approval

Experimental protocols were reviewed and approved by the Ethics Committee of the University of Cologne (no. 13-091), University Hosital Rouen (DC 2008_689), and Gazi University (no. 77082166-604.01.02-2017-03).

Conflict of interest

All authors and coauthors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Histologic features of ameloblastomas analyzed in this study. a Follicular ameloblastoma showing tumor islands with peripheral columnar cells and stellate reticulum-like cells (H&E, magnification ×100). b Plexiform ameloblastoma showing long anatomizing cords of ameloblastic epithelium (H&E, magnification ×100). c Intraluminal unicystic ameloblastoma lined by ameloblastic epithelium with luminal projections, no evidence of stromal invasion (H&E, magnification ×100). d Peripheral ameloblastoma showing tumor islands just underneath the oral mucosal epithelium (H&E, magnification ×100)
Fig. 2
Fig. 2
Overview of genomic alterations in ameloblastomas. Distribution of mutated genes with regard to anatomic location. Colored boxes indicate the presence of mutations in the genes listed on the left; columns indicate the respective cases. Prevalence of gene mutations
Fig. 3
Fig. 3
Distribution of mutations with regard to geographic regions. TK cases from Turkey, G + F cases from Germany and France

References

    1. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. Am J Clin Oncol. 2007;30(6):645–648. doi: 10.1097/COC.0b013e3181573e59. - DOI - PubMed
    1. Regezi J, Schiubba JJ, Jordon JRK. Oral pathology. Clinical pathologic correlations. 6. St. Louis: Elsevier-Saunders; 2012. pp. 270–277.
    1. Black CC, Addante RR, Mohila C. Intraosseous ameloblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(5):585–592. doi: 10.1016/j.tripleo.2010.02.040. - DOI - PubMed
    1. Gardner DG, Heikinheimo K, Shear M, Philipsen HP, Coleman H. Ameloblastomas. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumors. Pathology and genetics. Head and neck tumors. Lyon: IARC Press; 2005. pp. 296–300.
    1. Wright JM, Vered M. Update from 4th edition of the World Health Organization classification of head and neck tumors: odontogenic and maxillafacial bone. Head and Neck Pathol. 2017;11(1):68–77. doi: 10.1007/s12105-017-0794-1. - DOI - PMC - PubMed

LinkOut - more resources